Tirapazamine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tirapazamine
Skeletal formula
Space-filling model
Systematic (IUPAC) name
4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine
Clinical data
Legal status
?
Identifiers
CAS number 27314-97-2 YesY
ATC code None
PubChem CID 33776
ChemSpider 10437748 N
UNII 1UD32YR59G N
KEGG D06167 YesY
ChEBI CHEBI:78887 N
ChEMBL CHEMBL50882 N
Chemical data
Formula C7H6N4O2 
Mol. mass 178.148 g/mol
 N (what is this?)  (verify)

Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.[1][2]

Chemically it is an aromatic heterocycle di-N-oxide. Its full chemical name is 3-amino-1,2,4-benzotriazine-1,4 dioxide. Originally it was prepared in a programme screening for new herbicides in 1972. Its clinical use was first described by Zeman et al. in 1986.[3] While tirapazamine has had only limited effectiveness in clinical trials,[4] it has been used as a lead compound to develop a number of newer compounds with improved anti-cancer properties.[5]

An update of a Phase III trial (Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group) found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improved overall survival.[6]

References[edit]

  1. ^ Denny, WA (2004). "Prospects for hypoxia-activated anticancer drugs". Current Medicinal Chemistry 4 (5): 395–9. doi:10.2174/1568011043352812. PMID 15379691. 
  2. ^ Gandara, DR; Lara Jr, PN; Goldberg, Z; Le, QT; Mack, PC; Lau, DH; Gumerlock, PH (2002). "Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia". Seminars in oncology 29 (1 Suppl 4): 102–9. doi:10.1053/sonc.2002.31531. PMID 11894020. 
  3. ^ Zeman, EM; Brown, JM; Lemmon, MJ; Hirst, VK; Lee, WW (1986). "SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells". International journal of radiation oncology, biology, physics 12 (7): 1239–42. doi:10.1016/0360-3016(86)90267-1. PMID 3744945. 
  4. ^ Reddy, SB; Williamson, SK (January 2009). "Tirapazamine: a novel agent targeting hypoxic tumor cells". Expert Opinion on Investigational Drugs 18 (1): 77–87. doi:10.1517/13543780802567250. PMID 19053884. 
  5. ^ Hay, MP; Hicks, KO; Pchalek, K; Lee, HH; Blaser, A; Pruijn, FB; Anderson, RF; Shinde, SS et al. (November 2008). "Tricyclic 1,2,4Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins". Journal of Medicinal Chemistry 51 (21): 6853–65. doi:10.1021/jm800967h. PMC 2690574. PMID 18847185. 
  6. ^ Rischin, D; Peters, LJ; O'Sullivan, B; Giralt, J; Fisher, R; Yuen, K; Trotti, A; Bernier, J et al. (2010). "Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group". Journal of clinical oncology 28 (18): 2989–95. doi:10.1200/JCO.2009.27.4449. PMID 20479425. 

External links[edit]